News & Presentations

UPCOMING EVENTS

CORPORATE PRESENTATIONS

Date Title Documents

Corporate Presentation – July

AR-13324-CS208 Japan Phase 2 Study Topline Results

Topline Results from Rhopressa® (netarsudil ophthalmic solution) 0.02% Phase 4 Multi-center Open-label Study (MOST)

News Releases

Date Title and Summary Additional Formats
Toggle Summary Aerie Pharmaceuticals to Announce Second Quarter 2020 Financial Results and Host Conference Call on Thursday, August 6, 2020
DURHAM, N.C. --(BUSINESS WIRE)--Jul. 30, 2020-- Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases and
View HTML
Toggle Summary Aerie Pharmaceuticals Reports Positive Topline Results for AR-1105 (Dexamethasone Intravitreal Implant) Phase 2 Clinical Trial in Patients with Macular Edema Due to Retinal Vein Occlusion
DURHAM, N.C. --(BUSINESS WIRE)--Jul. 27, 2020-- Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases and
View HTML
Toggle Summary Aerie Pharmaceuticals Appoints Peter J. McDonnell, M.D., to the Company’s Board of Directors
DURHAM, N.C. --(BUSINESS WIRE)--Jun. 11, 2020-- Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, dry eye, retinal diseases
View HTML
Toggle Summary Aerie Pharmaceuticals Reports First Quarter 2020 Financial Results and Provides Business Update
Conference Call and Webcast Today, May 6 th , at 5:00 p.m. ET DURHAM, N.C. --(BUSINESS WIRE)--May 6, 2020-- Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of
View HTML
TOP